Adefovir serum levels do not differ between responders and nonresponders.
J Viral Hepat
; 18(7): e175-8, 2011 Jul.
Article
em En
| MEDLINE
| ID: mdl-21692930
ABSTRACT
Primary or secondary failure of adefovir dipivoxil (ADV) therapy of chronic hepatitis B is not infrequent. The reasons for suboptimal responses are not well defined. In HIV and hepatitis C virus infection, failure of antiviral drug therapy has been linked with low blood drug levels. We have studied 20 well-defined patients with chronic hepatitis B who were treated with ADV for drug and virus kinetics. Importantly, neither Cmax levels (mean 26 ng/mL, range 14-59 ng/mL) nor the time to maximal drug levels (mean 4 h, range 2-8 h) differed between patients showing a complete virological response to adefovir (n = 10), patients with secondary treatment failure (n = 7) and patients with suboptimal primary response (hepatitis B virus-DNA >10,000 IU/mL after 6 months of treatment; n = 3). Thus, adefovir treatment failure is unlikely to be due to an inability to mount sufficient drug levels in the blood.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Adenina
/
Hepatite B Crônica
/
Organofosfonatos
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article